Four years after winning an FDA approval for Koselugo to treat children with the rare disorder neurofibromatosis type 1 (NF1) ...

Daiichi showed the mechanism can work in TGCT years ago, publishing phase 3 data in 2018 and winning FDA approval for Turalio ...

With an array of new medicines and medical devices on display, global medical companies are looking to tap further into the ...

"China market is one of the most attractive markets for Edwards," said Leo Tam, senior director of the business unit of Transcatheter Aortic Valve Replacement, Edwards Lifesciences China, citing a lot ...

Award recipients to receive in-kind technologies and services to accelerate therapeutics to market <li /> Merck e ...

Merck is committed to supporting exceptional biotech companies to both kickstart and streamline their journey from discovery ...

Merck & Co. Inc.'s stock fell 3% Thursday, after the drug company beat profit and sales estimates for the third quarter, but lowered guidance due to charges stemming from deals with partners Curon ...

Merck & Co. Inc.'s stock swung between gains and losses premarket Thursday, after the drug company beat profit and sales estimates for the third quarter, but lowered guidance due to deals with ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

Antiviral Immunoglobulin Market. The global antiviral immunoglobulin market was valued at USD 4.6 billion in 2022 and is ...

Japanese drugmaker Shionogi (OTCPK:SGIOY) said a Phase 3 study has shown its antiviral drug Xocova was effective ... Xocova belongs to the same class of drugs as Pfizer’s (PFE) Paxlovid and Merck’s ...